← Leaderboards
Louis J. Picker
Oregon Health And Science University
$102,909,472
Attributed
$163,038,863
Total exposure
79
Grants
65
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $20.7M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$218,167,612 · 83
By mechanism
UM1$107,929,202 · 3
P01$53,849,644 · 12
R01$20,241,809 · 7
U19$17,748,158 · 4
R37$9,812,046 · 1
P51$8,080,747 · 54
Top collaborators
- Steven Grant Deeks10 shared
- Dan H. Barouch6 shared
- Sharon Ruth Lewin5 shared
- Janko Nikolich-Zugich4 shared
- Serena S Spudich1 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Jeffrey A Kaye$37,623,827
- Joseph F Quinn$13,031,665
- Daniel N Streblow$31,877,942
- Linda Boise$3,795,790
- Fred L Heffron$7,853,071
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaInfectionVaccinesT-LymphocyteViralVectorImmuneCytomegalovirusImmune ResponseResponseCellsT Cell ResponseMemoryMediatingProgramsVirusT Memory CellVaccinatedImmunologicsNonhuman PrimateBaseTissuesPatternUnited States National Institutes Of Health
Grant awards (180)
Immunologic and Virologic Basis of RhCMV/SIV Vaccine-Induced Replication Arrest Efficacy$5,243,013
P01 · FY2025 · AI · contact PI
Delaney AIDS Research Enterprise to Cure HIV$4,998,394
UM1 · FY2025 · AI
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacy$816,338
P01 · FY2025 · AI · contact PI
Project 1: Systemic analysis of the origin and tissue effects of the 68-1 RhCMV/SIV vaccine efficacy-predictive whole blood transcriptomic signature$388,685
P01 · FY2025 · AI · contact PI
Admin Core$231,849
P01 · FY2025 · AI · contact PI
Immunologic and Virologic Basis of RhCMV/SIV Vaccine-Induced Replication Arrest Efficacy$5,680,158
P01 · FY2024 · AI · contact PI
Delaney AIDS Research Enterprise to Cure HIV$5,455,521
UM1 · FY2024 · AI
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacy$619,903
P01 · FY2024 · AI · contact PI
Admin Core$202,786
P01 · FY2024 · AI · contact PI
Delaney AIDS Research Enterprise to Cure HIV$5,452,430
UM1 · FY2023 · AI
Immunologic and Virologic Basis of RhCMV/SIV Vaccine-Induced Replication Arrest Efficacy$5,039,342
P01 · FY2023 · AI · contact PI
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacy$471,466
P01 · FY2023 · AI · contact PI
Project 1: Systemic analysis of the origin and tissue effects of the 68-1 RhCMV/SIV vaccine efficacy-predictive whole blood transcriptomic signature$405,988
P01 · FY2023 · AI · contact PI
Admin Core$201,657
P01 · FY2023 · AI · contact PI
Delaney AIDS Research Enterprise to Cure HIV$5,448,894
UM1 · FY2022 · AI
Immunologic and Virologic Basis of RhCMV/SIV Vaccine-Induced Replication Arrest Efficacy$4,983,192
P01 · FY2022 · AI · contact PI
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacy$430,365
P01 · FY2022 · AI · contact PI
Admin Core$203,523
P01 · FY2022 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$8,268,168
UM1 · FY2021 · AI
Delaney AIDS Research Enterprise to Cure HIV$5,612,699
UM1 · FY2021 · AI
Development of Immunogenicity- and Efficacy-Optimized CMV Vectors for an HIV/AIDS Vaccine$2,321,981
U19 · FY2021 · AI · contact PI
Immunogenicity, Efficacy and Immune Correlates Analysis of Modified Cytomegalovirus Vectors That Differentially Elicit Unconventional CD8+ T Cell Responses in Rhesus Macaques$332,007
U19 · FY2021 · AI · contact PI
Administrative Core A$149,793
U19 · FY2021 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$8,268,211
UM1 · FY2020 · AI
Delaney AIDS Research Enterprise to Cure HIV$5,544,984
UM1 · FY2020 · AI
Development of Immunogenicity- and Efficacy-Optimized CMV Vectors for an HIV/AIDS Vaccine$2,321,982
U19 · FY2020 · AI · contact PI
Critical Role of Cytotoxic T Cells in HIV Neuropathogenesis$545,602
R01 · FY2020 · MH · contact PI
Immunogenicity, Efficacy and Immune Correlates Analysis of Modified Cytomegalovirus Vectors That Differentially Elicit Unconventional CD8+ T Cell Responses in Rhesus Macaques$480,286
U19 · FY2020 · AI · contact PI
Administrative Core A$141,355
U19 · FY2020 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$8,756,867
UM1 · FY2019 · AI
Delaney AIDS Research Enterprise to Cure HIV$5,797,109
UM1 · FY2019 · AI
Development of Immunogenicity- and Efficacy-Optimized CMV Vectors for an HIV/AIDS Vaccine$2,321,982
U19 · FY2019 · AI · contact PI
Immunogenicity, Efficacy and Immune Correlates Analysis of Modified Cytomegalovirus Vectors That Differentially Elicit Unconventional CD8+ T Cell Responses in Rhesus Macaques$480,286
U19 · FY2019 · AI · contact PI
Administrative Core A$141,350
U19 · FY2019 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$9,472,469
UM1 · FY2018 · AI
Delaney AIDS Research Enterprise to Cure HIV$5,547,114
UM1 · FY2018 · AI
Development of Immunogenicity- and Efficacy-Optimized CMV Vectors for an HIV/AIDS Vaccine$2,321,982
U19 · FY2018 · AI · contact PI
Immunogenicity, Efficacy and Immune Correlates Analysis of Modified Cytomegalovirus Vectors That Differentially Elicit Unconventional CD8+ T Cell Responses in Rhesus Macaques$480,286
U19 · FY2018 · AI · contact PI
Administrative Core A$141,355
U19 · FY2018 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$11,020,286
UM1 · FY2017 · AI
Delaney AIDS Research Enterprise to Cure HIV$5,493,761
UM1 · FY2017 · AI
Development of Immunogenicity- and Efficacy-Optimized CMV Vectors for an HIV/AIDS Vaccine$2,520,000
U19 · FY2017 · AI · contact PI
Role of Memory T Cell Dynamics in SIV Infection$974,775
R37 · FY2017 · AI · contact PI
Immunogenicity, Efficacy and Immune Correlates Analysis of Modified Cytomegalovirus Vectors That Differentially Elicit Unconventional CD8+ T Cell Responses in Rhesus Macaques$549,800
U19 · FY2017 · AI · contact PI
Administrative Core A$155,046
U19 · FY2017 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$7,245,181
UM1 · FY2016 · AI
Delaney AIDS Research Enterprise to Cure HIV$5,547,114
UM1 · FY2016 · AI
Development of an Effector-Memory T Cell AIDS Vaccine$3,475,833
P01 · FY2016 · AI · contact PI
Role of Memory T Cell Dynamics in SIV Infection$965,662
R37 · FY2016 · AI · contact PI
Enhancing RhCMV/SIV Vector Efficacy$655,760
P01 · FY2016 · AI · contact PI
Administration Core$148,496
P01 · FY2016 · AI · contact PI
Development of an Effector-Memory T Cell AIDS Vaccine$3,342,436
P01 · FY2015 · AI · contact PI
Role of Memory T Cell Dynamics in SIV Infection$963,517
R37 · FY2015 · AI · contact PI
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors$843,131
R01 · FY2015 · AI · contact PI
Efficacy of Oral CMV/SIV Vectors$775,096
R01 · FY2015 · DE · contact PI
CMV Vectors and Early Control of Mucosal SIV Challenge$573,995
U19 · FY2015 · AI · contact PI
Enhancing RhCMV/SIV Vector Efficacy$561,373
P01 · FY2015 · AI · contact PI
Administration Core$133,990
P01 · FY2015 · AI · contact PI
Development of an Effector-Memory T Cell AIDS Vaccine$3,377,368
P01 · FY2014 · AI · contact PI
Efficacy of Oral CMV/SIV Vectors$1,072,161
R01 · FY2014 · DE · contact PI
Role of Memory T Cell Dynamics in SIV Infection$969,337
R37 · FY2014 · AI · contact PI
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors$831,245
R01 · FY2014 · AI · contact PI
CMV Vectors and Early Control of Mucosal SIV Challenge$594,934
U19 · FY2014 · AI · contact PI
Macaque Resources$511,779
P01 · FY2014 · AI · contact PI
Enhancing RhCMV/SIV Vector Efficacy$507,778
P01 · FY2014 · AI · contact PI
Administration Core$121,419
P01 · FY2014 · AI · contact PI
Development of an Effector-Memory T Cell AIDS Vaccine$3,383,558
P01 · FY2013 · AI · contact PI
Role of Memory T Cell Dynamics in SIV Infection$905,851
R37 · FY2013 · AI · contact PI
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors$759,095
R01 · FY2013 · AI · contact PI
Efficacy of Oral CMV/SIV Vectors$751,072
R01 · FY2013 · DE · contact PI
CMV Vectors and Early Control of Mucosal SIV Challenge$539,624
U19 · FY2013 · AI · contact PI
Enhancing RhCMV/SIV Vector Efficacy$452,556
P01 · FY2013 · AI · contact PI
Efficacy of Oral CMV/SIV Vectors$434,536
R01 · FY2013 · DE · contact PI
Macaque Resources$299,354
P01 · FY2013 · AI · contact PI
Administration Core$221,826
P01 · FY2013 · AI · contact PI
Development of an Effector-Memory T Cell AIDS Vaccine$3,392,992
P01 · FY2012 · AI · contact PI
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors$812,795
R01 · FY2012 · AI · contact PI
Efficacy of Oral CMV/SIV Vectors$788,255
R01 · FY2012 · DE · contact PI
Role of Memory T Cell Dynamics in SIV Infection$780,253
R37 · FY2012 · AI · contact PI
Rejuvenation of the T-cell compartment in aging primates$694,478
R01 · FY2012 · AI · contact PI
CMV Vectors and Early Control of Mucosal SIV Challenge$580,103
U19 · FY2012 · AI · contact PI
Enhancing RhCMV/SIV Vector Efficacy$448,962
P01 · FY2012 · AI · contact PI
Macaque Resources$333,412
P01 · FY2012 · AI · contact PI
Administration Core$219,641
P01 · FY2012 · AI · contact PI
Development of an Effector-Memory T Cell AIDS Vaccine$3,500,000
P01 · FY2011 · AI · contact PI
Role of Memory T Cell Dynamics in SIV Infection$1,067,213
R37 · FY2011 · AI · contact PI
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors$855,999
R01 · FY2011 · AI · contact PI
Efficacy of Oral CMV/SIV Vectors$817,129
R01 · FY2011 · DE · contact PI
Rejuvenation of the T-cell compartment in aging primates$714,414
R01 · FY2011 · AI · contact PI
CMV Vectors and Early Control of Mucosal SIV Challenge$600,011
U19 · FY2011 · AI · contact PI
Enhancing RhCMV/SIV Vector Efficacy$470,614
P01 · FY2011 · AI · contact PI
CMV VECTOR DESIGN AND DEVELOPMENT$243,563
P51 · FY2011 · RR · contact PI
HARNESSING INNATE IMMUNITY TO ENHANCE T-CELL INDUCING HIV VACCINES$243,563
P51 · FY2011 · RR · contact PI
IMMUNE CORRELATES OF PROTECTION AGAINST SIV INFECTION$243,563
P51 · FY2011 · RR · contact PI
Administration Core$239,230
P01 · FY2011 · AI · contact PI
EFFICACY OF ORAL CMV/SIV VECTORS$194,877
P51 · FY2011 · RR · contact PI
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$194,877
P51 · FY2011 · RR · contact PI
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$194,877
P51 · FY2011 · RR · contact PI
ASSESSMENT OF PD-I BLOCKADE AS A NEW IMMUNOTHERAPEUTIC APPROACH TO AIDS$121,782
P51 · FY2011 · RR · contact PI
REJUVENATION OF THE T-CELL COMPARTMENT IN AGING PRIMATES$58,239
P51 · FY2011 · RR · contact PI
Macaque Resources$2
P01 · FY2011 · AI · contact PI
Role of Memory T Cell Dynamics in SIV Infection$1,061,520
R37 · FY2010 · AI · contact PI
Rejuvenation of the T-cell compartment in aging primates$663,398
R01 · FY2010 · AI · contact PI
Development of RhCMV Vectors for SIV Infection$500,000
R56 · FY2010 · AI · contact PI
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$190,131
P51 · FY2010 · RR · contact PI
HARNESSING INNATE IMMUNITY TO ENHANCE T-CELL INDUCING HIV VACCINES$190,131
P51 · FY2010 · RR · contact PI
CMV VECTOR DESIGN AND DEVELOPMENT$190,131
P51 · FY2010 · RR · contact PI
IMMUNE CORRELATES OF PROTECTION AGAINST SIV INFECTION$152,161
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$152,161
P51 · FY2010 · RR · contact PI
ASSESSMENT OF PD-I BLOCKADE AS A NEW IMMUNOTHERAPEUTIC APPROACH TO AIDS$95,066
P51 · FY2010 · RR · contact PI
AIDS MACAQUE RESOURCE$95,066
P51 · FY2010 · RR · contact PI
REJUVENATION OF THE T-CELL COMPARTMENT IN AGING PRIMATES$76,080
P51 · FY2010 · RR · contact PI
Macaque Resources$1
P01 · FY2010 · AI · contact PI
Role of Memory T Cell Dynamics in SIV Infection$1,076,069
R37 · FY2009 · AI · contact PI
Rejuvenation of the T-cell compartment in aging primates$722,375
R01 · FY2009 · AI · contact PI
Development of RhCMV Vectors for SIV Infection$328,000
R01 · FY2009 · AI · contact PI
IMMUNE CORRELATES OF PROTECTION AGAINST SIV INFECTION$267,602
P51 · FY2009 · RR · contact PI
HARNESSING INNATE IMMUNITY TO ENHANCE T-CELL INDUCING HIV VACCINES$206,673
P51 · FY2009 · RR · contact PI
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$165,284
P51 · FY2009 · RR · contact PI
CMV VECTOR DESIGN AND DEVELOPMENT$165,284
P51 · FY2009 · RR · contact PI
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$165,284
P51 · FY2009 · RR · contact PI
ASSESSMENT OF PD-I BLOCKADE AS A NEW IMMUNOTHERAPEUTIC APPROACH TO AIDS$124,031
P51 · FY2009 · RR · contact PI
DEVELOPMENT OF A JANUS KINASE 3 (JAK3) INHIBITOR FOR USE IN RHESUS MACAQUES$88,613
P51 · FY2009 · RR · contact PI
AIDS MACAQUE RESOURCE$88,613
P51 · FY2009 · RR · contact PI
DEVELOPMENT AND VALIDATION OF IMMUNOLOGIC TOOLS IN NONHUMAN PRIMATES$51,566
P51 · FY2009 · RR · contact PI
Macaque Resources$1
P01 · FY2009 · AI · contact PI
Vaccination and immune senescence in primates$1,902,930
P01 · FY2008 · AG · contact PI
Role of Memory T Cell Dynamics in SIV Infection$1,047,849
R37 · FY2008 · AI · contact PI
Development of RhCMV Vectors for SIV Infection$652,770
R01 · FY2008 · AI · contact PI
IMMUNE CORRELATES OF PROTECTION AGAINST SIV INFECTION$344,157
P51 · FY2008 · RR · contact PI
CMV IMMUNITY AND IMMUNE SENESCENCE IN PRIMATES$302,018
P01 · FY2008 · AG · contact PI
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$176,141
P51 · FY2008 · RR · contact PI
CMV VECTOR DESIGN AND DEVELOPMENT$176,141
P51 · FY2008 · RR · contact PI
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$176,141
P51 · FY2008 · RR · contact PI
HARNESSING INNATE IMMUNITY TO ENHANCE T-CELL INDUCING HIV VACCINES$176,141
P51 · FY2008 · RR · contact PI
AIDS MACAQUE RESOURCE$88,123
P51 · FY2008 · RR · contact PI
DEVELOPMENT OF A JANUS KINASE 3 (JAK3) INHIBITOR FOR USE IN RHESUS MACAQUES$88,123
P51 · FY2008 · RR · contact PI
DEVELOPMENT AND VALIDATION OF IMMUNOLOGIC TOOLS IN NONHUMAN PRIMATES$35,312
P51 · FY2008 · RR · contact PI
Development of RhCMV Vectors for SIV Infection$720,581
R01 · FY2007 · AI · contact PI
Role of memory T cell dynamics in SIV infection$716,501
R01 · FY2007 · AI · contact PI
CMV IMMUNITY AND IMMUNE SENESCENCE IN PRIMATES$301,248
P01 · FY2007 · AG · contact PI
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$225,890
P51 · FY2007 · RR · contact PI
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$225,890
P51 · FY2007 · RR · contact PI
HARNESSING INNATE IMMUNITY TO ENHANCE T-CELL INDUCING HIV VACCINES$56,513
P51 · FY2007 · RR · contact PI
CMV VECTOR DESIGN AND DEVELOPMENT$43,575
P51 · FY2007 · RR · contact PI
PILOT PROJECT FOR LIVE ATTENUATED VACCINE IMMUNE CORRELATES - IAVI$43,575
P51 · FY2007 · RR · contact PI
DEVELOPMENT AND VALIDATION OF IMMUNOLOGIC TOOLS IN NONHUMAN PRIMATES$43,574
P51 · FY2007 · RR · contact PI
INTERFERENCE WITH SIV PATHOGENESIS BY GENE THERAPY$43,574
P51 · FY2007 · RR · contact PI
Role of memory T cell dynamics in SIV infection$728,846
R01 · FY2006 · AI · contact PI
Development of RhCMV Vectors for SIV Infection$670,407
R01 · FY2006 · AI · contact PI
AIDS MACAQUE RESOURCE$262,324
P51 · FY2006 · RR · contact PI
CMV IMMUNITY AND IMMUNE SENESCENCE IN PRIMATES$236,679
P01 · FY2006 · AG · contact PI
INTERFERENCE WITH SIV PATHOGENESIS BY GENE THERAPY$131,162
P51 · FY2006 · RR · contact PI
DEVELOPMENT AND VALIDATION OF IMMUNOLOGIC TOOLS IN NONHUMAN PRIMATES$131,162
P51 · FY2006 · RR · contact PI
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$131,162
P51 · FY2006 · RR · contact PI
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$131,162
P51 · FY2006 · RR · contact PI
Role of memory T cell dynamics in SIV infection$766,080
R01 · FY2005 · AI
Development of RhCMV Vectors for SIV Infection$662,943
R01 · FY2005 · AI
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$285,035
P51 · FY2005 · RR
CMV IMMUNITY AND IMMUNE SENESCENCE IN PRIMATES$197,712
P01 · FY2005 · AG
DEVELOPMENT AND VALIDATION OF IMMUNOLOGIC TOOLS IN NONHUMAN PRIMATES$190,772
P51 · FY2005 · RR
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$94,156
P51 · FY2005 · RR
FUNCTION AND HOMEOSTASIS OF VIRAL PATHOGEN-SPECIFIC CD4+ MEMORY T CELLS$94,156
P51 · FY2005 · RR
AIDS MACAQUE RESOURCE$94,156
P51 · FY2005 · RR
FUNCTION AND HOMEOSTASIS OF VIRAL PATHOGEN-SPECIFIC CD4+ MEMORY T CELLS$3,562
M01 · FY2005 · RR
Role of memory T cell dynamics in SIV infection$746,964
R01 · FY2004 · AI
Development of RhCMV Vectors for SIV Infection$715,032
R01 · FY2004 · AI
CMV IMMUNITY AND IMMUNE SENESCENCE IN PRIMATES$192,411
P01 · FY2004 · AG
EVOLUTION OF T CELL RESPONSES IN PATHOGENIC AND ATTENUATED SIV INFECTION$105,323
P51 · FY2004 · RR
DEVELOPMENT OF RHCMV VECTORS FOR SIV INFECTION$105,323
P51 · FY2004 · RR
IL-15 AND THE CONTROL OF MEMORY T CELL TURNOVER IN RHESUS MACAQUES$105,323
P51 · FY2004 · RR
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$105,323
P51 · FY2004 · RR
VIROLOGIC AND IMMUNOLOGIC PARAMETERS OF RHESUS CMV INFECTION$105,323
P51 · FY2004 · RR
FUNCTION AND HOMEOSTASIS OF VIRAL PATHOGEN-SPECIFIC CD4+ MEMORY T CELLS$105,323
P51 · FY2004 · RR
FUNCTION AND HOMEOSTASIS OF VIRAL PATHOGEN-SPECIFIC CD4+ MEMORY T. CELLS$2,444
M01 · FY2004 · RR
ROLE OF MEMORY T CELL DYNAMICS IN SIV INFECTION$1,474
P51 · FY2004 · RR
Role of memory T cell dynamics in SIV infection$692,773
R01 · FY2003 · AI
FUNCTION &HOMEOSTASIS OF VIRAL PATHOGEN-SPECIFIC CD4+$259,223
R01 · FY2002 · AI
FUNCTION &HOMEOSTASIS OF VIRAL PATHOGEN-SPECIFIC CD4+$253,321
R01 · FY2001 · AI
FUNCTION &HOMEOSTASIS OF VIRAL PATHOGEN-SPECIFIC CD4+$247,587
R01 · FY2000 · AI